(Albany, US) DelveInsight has launched a new report on “Hyperuricemia Pipeline Insight, 2020”.
“Hyperuricemia Pipeline Insight, 2020” report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Hyperuricemia market. A detailed picture of the Hyperuricemia pipeline landscape is provided, which includes the disease overview and Hyperuricemia treatment guidelines.
The assessment part of the report embraces in-depth Hyperuricemia commercial assessment and clinical assessment of the Hyperuricemia pipeline products from the pre-clinical developmental phase to the marketed phase. In the report, a detailed description of the drug is proffered including mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Hyperuricemia collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.
The major players covered in the hyperuricemia drugs market are:
- Takeda Pharmaceutical Company Limited
- Mylan N.V.
- Sun Pharmaceutical Industries Limited
- Hikma Pharmaceutical PLC
- Dr. Reddy’s Laboratories Ltd
- Sanofi
- Sandoz AG
- Amneal Pharmaceuticals LLC
- And Many Others
Request for free sample report: https://www.delveinsight.com/sample-request/hyperuricemia-pipeline-insight
Scope of the report
- The Hyperuricemia report provides an overview of therapeutic pipeline activity and therapeutic assessment of the products by development stage, product type, route of administration, molecule type, and MOA type for Hyperuricemia across the complete product development cycle, including all clinical and nonclinical stages.
- It comprises of detailed profiles of Hyperuricemia therapeutic products with key coverage of developmental activities, including technology, collaborations, licensing, mergers and acquisition, funding, designations and other product-related details
- Detailed Hyperuricemia research and development progress and trial details, results wherever available, are also included in the pipeline study.
- Coverage of dormant and discontinued pipeline projects along with the reasons if available across Hyperuricemia.
Request for free sample report: https://www.delveinsight.com/sample-request/hyperuricemia-pipeline-insight
Hyperuricemia occurs when there’s too much uric acid in your blood. High uric acid levels can lead to several diseases, including a painful type of arthritis called gout. Elevated uric acid levels are also associated with health conditions such as heart disease, diabetes, and kidney disease.
Uric acid is formed when purines break down in your body. Purines are chemicals found in certain foods. This typically includes:
- red meat
- organ meat
- seafood
- beans
Normally, your body rids itself of uric acid when you urinate. Hyperuricemia occurs when your body either makes too much uric acid or is unable to excrete enough of it. It usually happens because your kidneys aren’t eliminating it quickly enough.
Excess uric acid levels in your blood can lead to the formation of crystals. Although these can form anywhere in the body, they tend to form in and around your joints and in your kidneys. Your body’s defensive white blood cells may attack the crystals, causing inflammation and pain.
Rates of hyperuricemia have risen sharply since 1960.
Request for free sample report: https://www.delveinsight.com/sample-request/hyperuricemia-pipeline-insight
Table of Contents:
1. Report Introduction
2. Hyperuricemia
2.1. Overview
2.2. History
2.3. Hyperuricemia Symptoms
2.4. Causes
2.5.Pathophysiology
2.6. Hyperuricemia Diagnosis
2.6.1. Diagnostic Guidelines
3. Hyperuricemia Current Treatment Patterns
3.1. Hyperuricemia Treatment Guidelines
4. Hyperuricemia – DelveInsight’s Analytical Perspective
4.1. In-depth Commercial Assessment
4.1.1. Hyperuricemia companies collaborations, Licensing, Acquisition -Deal Value Trends
4.1.1.1. Assessment Summary
4.1.2. Hyperuricemia Collaboration Deals
4.1.2.1. Company-Company Collaborations (Licensing / Partnering) Analysis
4.1.2.2. Company-University Collaborations (Licensing / Partnering) Analysis
4.1.2.3. Hyperuricemia Acquisition Analysis
5. Therapeutic Assessment
5.1. Clinical Assessment of Pipeline Drugs
5.1.1. Assessment by Phase of Development
5.1.2. Assessment by Product Type (Mono / Combination)
5.1.2.1. Assessment by Stage and Product Type
5.1.3. Assessment by Route of Administration
5.1.3.1. Assessment by Stage and Route of Administration
5.1.4. Assessment by Molecule Type
5.1.4.1. Assessment by Stage and Molecule Type
5.1.5. Assessment by MOA
5.1.5.1. Assessment by Stage and MOA
5.1.6. Assessment by Target
5.1.6.1. Assessment by Stage and Target
6. Hyperuricemia Late Stage Products (Phase-III)
7. Hyperuricemia Mid Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Hyperuricemia Discontinued Products
13. Hyperuricemia Product Profiles
13.1. Drug Name: Company
13.1.1. Product Description
13.1.1.1. Product Overview
13.1.1.2. Mechanism of action
13.1.2. Research and Development
13.1.2.1. Clinical Studies
13.1.3. Product Development Activities
13.1.3.1. Collaboration
13.1.3.2. Agreements
13.1.3.3. Acquisition
13.1.3.4. Patent Detail
13.1.4. Tabulated Product Summary
13.1.4.1. General Description Table
Detailed information in the report?
14. Hyperuricemia Key Companies
15. Hyperuricemia Key Products
16. Dormant and Discontinued Products
16.1. Dormant Products
16.1.1. Reasons for being dormant
16.2. Discontinued Products
16.2.1. Reasons for the discontinuation
17. Hyperuricemia Unmet Needs
18. Hyperuricemia Future Perspectives
19. Hyperuricemia Analyst Review
20. Appendix
21. Report Methodology
21.1. Secondary Research
21.2. Expert Panel Validation
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +19193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/report-store/hyperuricemia-pipeline-insight